1. Home
  2. STTK vs LOAN Comparison

STTK vs LOAN Comparison

Compare STTK & LOAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STTK
  • LOAN
  • Stock Information
  • Founded
  • STTK 2016
  • LOAN 1989
  • Country
  • STTK United States
  • LOAN United States
  • Employees
  • STTK N/A
  • LOAN N/A
  • Industry
  • STTK Biotechnology: Pharmaceutical Preparations
  • LOAN Real Estate Investment Trusts
  • Sector
  • STTK Health Care
  • LOAN Real Estate
  • Exchange
  • STTK Nasdaq
  • LOAN Nasdaq
  • Market Cap
  • STTK 56.8M
  • LOAN 63.3M
  • IPO Year
  • STTK 2020
  • LOAN 1999
  • Fundamental
  • Price
  • STTK $1.23
  • LOAN $5.52
  • Analyst Decision
  • STTK Hold
  • LOAN
  • Analyst Count
  • STTK 3
  • LOAN 0
  • Target Price
  • STTK $2.00
  • LOAN N/A
  • AVG Volume (30 Days)
  • STTK 127.4K
  • LOAN 12.8K
  • Earning Date
  • STTK 02-27-2025
  • LOAN 03-10-2025
  • Dividend Yield
  • STTK N/A
  • LOAN 8.33%
  • EPS Growth
  • STTK N/A
  • LOAN 6.53
  • EPS
  • STTK N/A
  • LOAN 0.49
  • Revenue
  • STTK $6,435,000.00
  • LOAN $7,394,068.00
  • Revenue This Year
  • STTK $313.04
  • LOAN N/A
  • Revenue Next Year
  • STTK N/A
  • LOAN N/A
  • P/E Ratio
  • STTK N/A
  • LOAN $11.41
  • Revenue Growth
  • STTK 382.75
  • LOAN 5.79
  • 52 Week Low
  • STTK $0.94
  • LOAN $4.60
  • 52 Week High
  • STTK $11.76
  • LOAN $5.90
  • Technical
  • Relative Strength Index (RSI)
  • STTK 52.10
  • LOAN 48.61
  • Support Level
  • STTK $1.11
  • LOAN $5.43
  • Resistance Level
  • STTK $1.36
  • LOAN $5.60
  • Average True Range (ATR)
  • STTK 0.11
  • LOAN 0.09
  • MACD
  • STTK 0.01
  • LOAN -0.01
  • Stochastic Oscillator
  • STTK 56.67
  • LOAN 35.94

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.

About LOAN Manhattan Bridge Capital Inc

Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.

Share on Social Networks: